Literature DB >> 22081141

Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH.

Paola Lo Surdo1, Matthew J Bottomley, Alessandra Calzetta, Ethan C Settembre, Agostino Cirillo, Shilpa Pandit, Yan G Ni, Brian Hubbard, Ayesha Sitlani, Andrea Carfí.   

Abstract

The protein PCSK9 (proprotein convertase subtilisin/kexin type 9) is a key regulator of low-density lipoprotein receptor (LDLR) levels and cardiovascular health. We have determined the crystal structure of LDLR bound to PCSK9 at neutral pH. The structure shows LDLR in a new extended conformation. The PCSK9 C-terminal domain is solvent exposed, enabling cofactor binding, whereas the catalytic domain and prodomain interact with LDLR epidermal growth factor(A) and β-propeller domains, respectively. Thus, PCSK9 seems to hold LDLR in an extended conformation and to interfere with conformational rearrangements required for LDLR recycling.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22081141      PMCID: PMC3245695          DOI: 10.1038/embor.2011.205

Source DB:  PubMed          Journal:  EMBO Rep        ISSN: 1469-221X            Impact factor:   8.807


  35 in total

1.  Regulatory effects of peptides from the pro and catalytic domains of proprotein convertase subtilisin/kexin 9 (PCSK9) on low-density lipoprotein receptor (LDL-R).

Authors:  H Palmer-Smith; A Basak
Journal:  Curr Med Chem       Date:  2010       Impact factor: 4.530

2.  A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake.

Authors:  Yan G Ni; Jon H Condra; Laura Orsatti; Xun Shen; Stefania Di Marco; Shilpa Pandit; Matthew J Bottomley; Lionello Ruggeri; Richard T Cummings; Rose M Cubbon; Joseph C Santoro; Anka Ehrhardt; Dale Lewis; Timothy S Fisher; Sookhee Ha; Leila Njimoluh; Dana D Wood; Holly A Hammond; Douglas Wisniewski; Cinzia Volpari; Alessia Noto; Paola Lo Surdo; Brian Hubbard; Andrea Carfí; Ayesha Sitlani
Journal:  J Biol Chem       Date:  2010-02-19       Impact factor: 5.157

3.  In vivo evidence that furin from hepatocytes inactivates PCSK9.

Authors:  Rachid Essalmani; Delia Susan-Resiga; Ann Chamberland; Marianne Abifadel; John W Creemers; Catherine Boileau; Nabil G Seidah; Annik Prat
Journal:  J Biol Chem       Date:  2010-12-08       Impact factor: 5.157

4.  A two-step binding model of PCSK9 interaction with the low density lipoprotein receptor.

Authors:  Taichi Yamamoto; Christine Lu; Robert O Ryan
Journal:  J Biol Chem       Date:  2010-12-11       Impact factor: 5.157

5.  Model of human low-density lipoprotein and bound receptor based on cryoEM.

Authors:  Gang Ren; Gabby Rudenko; Steven J Ludtke; Johann Deisenhofer; Wah Chiu; Henry J Pownall
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-28       Impact factor: 11.205

6.  The epidermal growth factor homology domain of the LDL receptor drives lipoprotein release through an allosteric mechanism involving H190, H562, and H586.

Authors:  Zhenze Zhao; Peter Michaely
Journal:  J Biol Chem       Date:  2008-08-03       Impact factor: 5.157

7.  Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels.

Authors:  Gaétan Mayer; Steve Poirier; Nabil G Seidah
Journal:  J Biol Chem       Date:  2008-09-17       Impact factor: 5.157

8.  Mechanism of LDL binding and release probed by structure-based mutagenesis of the LDL receptor.

Authors:  Sha Huang; Lisa Henry; Yiu Kee Ho; Henry J Pownall; Gabby Rudenko
Journal:  J Lipid Res       Date:  2009-08-11       Impact factor: 5.922

9.  PCSK9: a convertase that coordinates LDL catabolism.

Authors:  Jay D Horton; Jonathan C Cohen; Helen H Hobbs
Journal:  J Lipid Res       Date:  2008-11-19       Impact factor: 5.922

Review 10.  Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease.

Authors:  Marianne Abifadel; Jean-Pierre Rabès; Martine Devillers; Arnold Munnich; Danièle Erlich; Claudine Junien; Mathilde Varret; Catherine Boileau
Journal:  Hum Mutat       Date:  2009-04       Impact factor: 4.878

View more
  72 in total

1.  New horizons for lipoprotein receptors: communication by β-propellers.

Authors:  Olav M Andersen; Robert Dagil; Birthe B Kragelund
Journal:  J Lipid Res       Date:  2013-07-23       Impact factor: 5.922

Review 2.  Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies.

Authors:  Nabil G Seidah; Annik Prat; Angela Pirillo; Alberico Luigi Catapano; Giuseppe Danilo Norata
Journal:  Cardiovasc Res       Date:  2019-03-01       Impact factor: 10.787

3.  Ser-Phosphorylation of PCSK9 (Proprotein Convertase Subtilisin-Kexin 9) by Fam20C (Family With Sequence Similarity 20, Member C) Kinase Enhances Its Ability to Degrade the LDLR (Low-Density Lipoprotein Receptor).

Authors:  Ali Ben Djoudi Ouadda; Marie-Soleil Gauthier; Delia Susan-Resiga; Emmanuelle Girard; Rachid Essalmani; Miles Black; Jadwiga Marcinkiewicz; Diane Forget; Josée Hamelin; Alexandra Evagelidis; Kevin Ly; Robert Day; Luc Galarneau; Francois Corbin; Benoit Coulombe; Artuela Çaku; Vincent S Tagliabracci; Nabil G Seidah
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-09-05       Impact factor: 8.311

4.  APP, APLP2 and LRP1 interact with PCSK9 but are not required for PCSK9-mediated degradation of the LDLR in vivo.

Authors:  Ting Fu; YangYang Guan; Junjie Xu; Yan Wang
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2017-05-09       Impact factor: 4.698

Review 5.  Vaccination against atherosclerosis.

Authors:  Kouji Kobiyama; Ryosuke Saigusa; Klaus Ley
Journal:  Curr Opin Immunol       Date:  2019-03-29       Impact factor: 7.486

Review 6.  The PCSK9 decade.

Authors:  Gilles Lambert; Barbara Sjouke; Benjamin Choque; John J P Kastelein; G Kees Hovingh
Journal:  J Lipid Res       Date:  2012-07-17       Impact factor: 5.922

Review 7.  How multi-scale structural biology elucidated context-dependent variability in ectodomain conformation along with the ligand capture and release cycle for LDLR family members.

Authors:  Terukazu Nogi
Journal:  Biophys Rev       Date:  2017-12-04

8.  Identification of roles for H264, H306, H439, and H635 in acid-dependent lipoprotein release by the LDL receptor.

Authors:  Hongyun Dong; Zhenze Zhao; Drake G LeBrun; Peter Michaely
Journal:  J Lipid Res       Date:  2016-11-28       Impact factor: 5.922

9.  Short- and long-term effects of xuezhikang, an extract of cholestin, on serum proprotein convertase subtilisin/kexin type 9 levels.

Authors:  Yan-jun Jia; Yan Zhang; Jun Liu; Yuan-lin Guo; Rui-xia Xu; Jian-jun Li
Journal:  Chin J Integr Med       Date:  2014-07-04       Impact factor: 1.978

Review 10.  Potential of proprotein convertase subtilisin/kexin type 9 based therapeutics.

Authors:  Evan A Stein; Gary D Swergold
Journal:  Curr Atheroscler Rep       Date:  2013-03       Impact factor: 5.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.